{"id":3182,"date":"2015-12-10T18:42:29","date_gmt":"2015-12-10T18:42:29","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=4931"},"modified":"2015-12-10T18:42:29","modified_gmt":"2015-12-10T18:42:29","slug":"retired-nfl-star-marvin-washington-leads-the-charge-in-show-your-green-a-kannalife-and-medical-marijuana-inc-psa-and-awareness-campaign-for-cte-research","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2015\/12\/10\/retired-nfl-star-marvin-washington-leads-the-charge-in-show-your-green-a-kannalife-and-medical-marijuana-inc-psa-and-awareness-campaign-for-cte-research\/","title":{"rendered":"Retired NFL Star Marvin Washington Leads the Charge in \u201cShow Your Green\u201d \u2013 A Kannalife and Medical Marijuana, Inc. PSA and Awareness Campaign for CTE Research"},"content":{"rendered":"
NEW YORK \u2013 December 10, 2015 \u2013 To address the public\u2019s questions about CTE, what the disease is and who\u00a0it impacts \u2014 Medical Marijuana, Inc. (OTC Pink: MJNA) and its portfolio company Kannalife Sciences, Inc.\u00a0(\u201cKannalife\u201d)<\/a>, a phyto-medical company involved in the research and development of novel therapeutic agents\u00a0designed to be neuroprotectants and immuno-modulators \u2014 are responding with a social media-driven\u00a0campaign titled \u201cShow Your Green.<\/a>\u201d<\/p>\n Leading the \u201cShow Your Green\u201d PSA is Kannalife\u2019s advisory board member and former NFL star defensive\u00a0lineman, Marvin Washington. From 1988 to 1999, Mr. Washington played in 155 games over 11 seasons in the\u00a0NFL, recording over 40 sacks in his eight years with the New York Jets, two years with the San Francisco 49\u2019ers\u00a0and as a member of the 1998 Superbowl champion Denver Broncos. Mr. Washington now leads Kannalife\u2019s\u00a0efforts to expand on raising awareness for the disease and the need for a community driven effort to support the\u00a0research and development of therapeutic treatments to fight CTE. Having been diagnosed with three known\u00a0concussions<\/a> and a countless number of subconcussions, the former NFL star is extremely passionate about\u00a0helping individuals who are battling the debilitating and often deadly effects of CTE.<\/p>\n In \u201cShow Your Green\u201d, Mr. Washington narrates the first of a short series of \u201cShow Your Green\u201d public awareness\u00a0campaign videos, as he shares facts about CTE including:<\/p>\n The \u201cShow Your Green\u201d awareness campaign call-to-action is to post a photo featuring green \u201ceye black\u201d and\u00a0then sharing the photo within the respondent\u2019s social sphere of influence. By watching \u201cShow Your Green\u201d, every\u00a0football fan from toddler to titan can have the opportunity to join in and show their green in support of increasing\u00a0awareness of CTE and the drive towards developing a treatment for concussive injury and CTE, a life threating\u00a0and debilitating disease. CTE is an oxidative stress (OS) related disease. Neural cells suffer functional or sensory\u00a0loss in neurodegenerative diseases. Apart from several other environmental or genetic factors, oxidative stress\u00a0leading to free radical attack on neural cells contributes a calamitous role in neurodegeneration.<\/p>\n Kannalife currently holds two licenses with National Institutes of Health for U.S. Patent 6,630,507 \u201cCannabinoids\u00a0as Antioxidants and Neuroprotectants.\u201d<\/a> These licenses are currently in use by Kannalife to develop novel\u00a0therapeutic drugs to treat chronic traumatic encephalopathy (CTE) and hepatic encephalopathy (HE). Kannalife\u2019s scientific team has researched the effects of\u00a0cannabidiol (CBD) on non-differentiated native neuronal cells and has determined cannabidiol\u2019s potential as a\u00a0target drug candidate to treat oxidative stress-related disorders, CBD\u2019s therapeutic index, and CBD\u2019s limitations\u00a0in pharmaceutical target drug design.<\/p>\n \u201cIt is a positive step forward to see increased social awareness of traumatic head injury and CTE as well as a\u00a0call-to-action by the public to creatively drive medical research for a solution,\u201d states Dr. Stuart Titus, Chief\u00a0Executive Officer of Medical Marijuana, Inc.<\/a> \u201cA head injury can affect people of all ages \u2013 not just NFL players.\u201d<\/p>\n Dr. Titus continues, \u201cKannalife\u2019s efforts are focused on developing a neuroprotective pharmaceutical compound\u00a0that may have far-reaching implications for furthering the science of neurological medicine. The Company aims\u00a0to improve quality of life for patients and sufferers of concussions and CTE. The end goal is to end the suffering\u00a0of patients and their families, who in later stages have been torn apart by the long-term degenerative effects of\u00a0this terrible condition.\u201d<\/p>\n In tandem with its findings on CBD, Kannalife has developed a new cannabidiol-like molecule called KLS-13019\u00a0that, through pre-clinical testing and pharmacokinetic (PK) studies, indicates improvement over CBD\u2019s role as a\u00a0neuroprotectant through increased potency, as well as potential for greater safety through reduced toxicity. Side-by-side comparisons between CBD and KLS-13019 have also shown that KLS-13019 has marked improvements\u00a0over CBD in oral bioavailability, CNS penetration, blood-plasma concentrations, and cognitive improvement in\u00a0murine behavioral models.<\/p>\n You can \u201cShow Your Green\u201d and assist in raising awareness in the fight for a cure for CTE though medical\u00a0research, by going to www.treatCTE.org<\/a> for details. Campaign spokespersons will be featured Friday, Dec. 11\u00a0at 9:00 am \u2013 9:27 am PT on the U-T Community Spotlight Radio Show; the live broadcast can be heard online\u00a0at www.wsradio.com<\/a>. An archive of the interview can be accessed at www.wsradio.com\/utsandiego<\/a>.<\/p>\n About Kannalife Sciences, Inc.<\/p>\n Kannalife Sciences, Inc. is a phyto-medical company involved in the research and development of novel\u00a0therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently conducting\u00a0research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug\u00a0candidates to treat Hepatic Encephalopathy (“HE”) and Chronic Traumatic Encephalopathy (“CTE”). HE and\u00a0CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information,\u00a0on Kannalife, please visit the company\u2019s website at: www.kannalife.com.<\/p>\n About Medical Marijuana Inc.<\/p>\n The mission of Medical Marijuana, Inc. (OTC Pink: MJNA) is to be the premier cannabis and hemp industry\u00a0innovator, leveraging our team of professionals to source, evaluate and purchase value-added companies and\u00a0products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness\u00a0within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing\u00a0shareholder value. For more information on Medical Marijuana, Inc., please visit the company’s website at:\u00a0www.medicalmarijuanainc.com<\/p>\n FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE<\/p>\n These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any\u00a0disease.<\/p>\n FORWARD-LOOKING DISCLAIMER<\/p>\n This press release may contain certain forward-looking statements and information, as defined within the\u00a0meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934,\u00a0and is subject to the Safe Harbor created by those sections. This material contains statements about expected\u00a0future events and\/or financial results that are forward-looking in nature and subject to risks and uncertainties.<\/p>\n Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause\u00a0the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the\u00a0statements made herein.<\/p>\n LEGAL DISCLOSURE<\/p>\n Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled\u00a0Substances Act (US.CSA). Their companies do grow, sell, and distribute hemp-based products and are involved\u00a0with the federally legal distribution of medical marijuana-based products within certain international markets.\u00a0Cannabidiol is a natural constituent of hemp oil. \t<\/p>\n","protected":false},"excerpt":{"rendered":" Public Service Announcement (PSA) Campaign Raises Awareness to Research a Possible Treatment for\u00a0Chronic Traumatic Encephalopathy (CTE) NEW YORK \u2013 December 10, 2015 \u2013 To address the public\u2019s questions about CTE, what the disease is and who\u00a0it impacts \u2014 Medical Marijuana, Inc. (OTC Pink: MJNA) and its portfolio company Kannalife Sciences, Inc.\u00a0(\u201cKannalife\u201d), a phyto-medical company involved […]<\/p>\n","protected":false},"author":1,"featured_media":3173,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[163,2],"tags":[179,49],"class_list":["post-3182","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-kannalife-sciences","category-press-releases","tag-kannalife-sciences","tag-medical-marijuana-inc"],"yoast_head":"\n\n